Short Interest in MaxCyte, Inc. (NASDAQ:MXCT) Rises By 55.1%

MaxCyte, Inc. (NASDAQ:MXCT) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 3,881,689 shares, an increase of 55.1% from the January 15th total of 2,503,062 shares. Based on an average daily trading volume, of 1,116,399 shares, the short-interest ratio is currently 3.5 days. Approximately 3.8% of the shares of the company are short sold. Approximately 3.8% of the shares of the company are short sold. Based on an average daily trading volume, of 1,116,399 shares, the short-interest ratio is currently 3.5 days.

Analyst Upgrades and Downgrades

MXCT has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.00.

Hedge Funds Weigh In On MaxCyte

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC raised its holdings in MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after purchasing an additional 5,836 shares during the period. BNP Paribas Financial Markets raised its stake in MaxCyte by 39.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock worth $57,000 after buying an additional 10,263 shares during the period. Kwmg LLC raised its stake in MaxCyte by 75.8% during the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after buying an additional 11,135 shares during the period. Prudential Financial Inc. bought a new position in MaxCyte during the second quarter worth about $26,000. Finally, May Hill Capital LLC acquired a new position in MaxCyte in the second quarter valued at about $27,000. 68.81% of the stock is owned by institutional investors.

MaxCyte Stock Down 1.9%

MaxCyte stock traded down $0.01 during mid-day trading on Friday, hitting $0.72. 1,262,423 shares of the company were exchanged, compared to its average volume of 1,382,774. The company has a market capitalization of $76.76 million, a PE ratio of -1.64 and a beta of 1.21. The business has a fifty day moving average of $1.28 and a 200 day moving average of $1.47. MaxCyte has a 1-year low of $0.68 and a 1-year high of $4.32.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The firm had revenue of $6.41 million during the quarter, compared to the consensus estimate of $8.37 million. MaxCyte had a negative net margin of 132.57% and a negative return on equity of 23.50%. Research analysts expect that MaxCyte will post -0.42 earnings per share for the current year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.